YIH
PTGX icon

Y-Intercept (HK)’s Protagonist Therapeutics PTGX Stock Holding History

Y-Intercept (HK)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,169
Closed -$975K – 1943
2025
Q1 		$975K Buy
+20,169
New +$845K 0.07% 416
2024
Q4 		– Sell
-5,251
Closed -$236K – 1562
2024
Q3 		$236K Sell
5,251
-42,876
-89% -$1.73M 0.01% 1099
2024
Q2 		$1.67M Buy
48,127
+26,678
+124% +$781K 0.09% 300
2024
Q1 		$621K Buy
+21,449
New +$584K 0.05% 602
2023
Q1 		– Sell
-14,318
Closed -$156K – 1468
2022
Q4 		$156K Sell
14,318
-7,077
-33% -$59.7K 0.02% 863
2022
Q3 		$180K Buy
+21,395
New +$202K 0.02% 837

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s PTGX Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 20,169 shares — an estimated $975K sold.

Y-Intercept (HK) first reported a position in PTGX in Q3 2022 and held it in 6 quarters. The position peaked at $1.67M in Q2 2024. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Y-Intercept (HK) reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 20,169 Protagonist Therapeutics shares in Q2 2025, an estimated $975K.
  • Y-Intercept (HK) first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 6 quarters.
  • Y-Intercept (HK)'s Protagonist Therapeutics position peaked at $1.67M in Q2 2024.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.